Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

TransCode Therapeutics, Inc. - Common Stock (NQ:RNAZ)

8.520 -0.150 (-1.73%)
Streaming Delayed Price Updated: 2:49 PM EDT, Apr 24, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about TransCode Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
News headline image
Dow Surges 150 Points, US Current Account Deficit Widens In Q3 ↗
 
Via Benzinga
Topics Stocks
News headline image
Peering Into TransCode Therapeutics's Recent Short Interest ↗
 
Via Benzinga
News headline image
Why TransCode Therapeutics (RNAZ) Stock Is Diving ↗
TransCode Therapeutics shares are trading lower by 16% during Monday's session. The company announced a 1-for-33 reverse stock split. 
Via Benzinga
News headline image
TransCode Therapeutics Announces Effective Date for 1-for-33 Reverse Stock Split
From TransCode Therapeutics, Inc.
Via GlobeNewswire
News headline image
TransCode Therapeutics, Inc. Announces $8 Million Private Placement
From TransCode Therapeutics, Inc.
Via GlobeNewswire
News headline image
Why Transcode Therapeutics (RNAZ) Stock Is Moving ↗
Transcode Therapeutics shares are trading lower by 11% to 34 cents Monday afternoon. The company announced its Board's approval of a 1-for-33 reverse stock split. 
Via Benzinga
News headline image
TransCode Therapeutics Announces 1-for-33 Reverse Stock Split
Split designed to achieve compliance with Nasdaq minimum bid price requirements 
From TransCode Therapeutics, Inc.
Via GlobeNewswire
News headline image
TransCode Therapeutics Open Letter to Shareholders
From TransCode Therapeutics, Inc.
Via GlobeNewswire
News headline image
TransCode Therapeutics Announces Nasdaq Extension to Regain Compliance
From TransCode Therapeutics, Inc.
Via GlobeNewswire
News headline image
TransCode Therapeutics Announces Safety Review Committee Approval of Second Cohort Opening in Phase 1 TTX-MC138 Clinical Trial Following Favorable Review of Cohort 1 Safety Data
From TransCode Therapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
TransCode Therapeutics Completes Initial Dosing of First Cohort in Phase 1 Clinical Trial with TTX-MC138, a microRNA-Targeted Technology
From TransCode Therapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
TransCode Therapeutics Announces First Patients Treated in Phase 1 Clinical Trial with First-in-Class Lead Therapeutic Candidate
From TransCode Therapeutics, Inc.
Via GlobeNewswire
News headline image
TransCode Therapeutics Announces Publication of Study with Lead Therapeutic Candidate Revealing Mechanisms Behind Candidate’s Preclinical Efficacy Against Metastatic Cancer
Study demonstrates that TransCode’s lead therapeutic candidate, TTX-MC138, reduces tumor cell capacity for self-renewal 
From TransCode Therapeutics, Inc.
Via GlobeNewswire
News headline image
TransCode Therapeutics Awarded $2 Million NIH Grant to Support Clinical Evaluation of Lead Candidate
Grant awarded by the National Cancer Institute (NCI) of the NIH to support clinical development of lead therapeutic candidate, TTX-MC138 
From TransCode Therapeutics, Inc.
Via GlobeNewswire
News headline image
RNAZ Stock Earnings: TransCode Therapeutics Misses EPS for Q2 2024 ↗
RNAZ stock results show that TransCode Therapeutics missed analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
News headline image
TransCode Therapeutics Announces Phase 1 Clinical Trial Initiation
From TransCode Therapeutics, Inc.
Via GlobeNewswire
News headline image
Why Pitney Bowes Shares Are Trading Higher By Over 12%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
TransCode Therapeutics, Inc. Announces Closing of Public Offering
From TransCode Therapeutics, Inc.
Via GlobeNewswire
News headline image
Gold Moves Higher; Coca-Cola Increases FY24 Forecast ↗
 
Via Benzinga
News headline image
Why Transcode Therapeutics (RNAZ) Stock Is Down 60% ↗
Transcode Therapeutics shares are trading lower by 62% during Tuesday's session. The company announced pricing of its public offering. 
Via Benzinga
News headline image
Why Comcast Shares Are Trading Lower By 6%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
 
Via Benzinga
News headline image
Crude Oil Down 2%; GE Aerospace Earnings Top Views ↗
 
Via Benzinga
News headline image
US Stocks Edge Higher; General Motors Posts Upbeat Earnings ↗
 
Via Benzinga
News headline image
Why Is Mira Pharmaceuticals (MIRA) Stock Down 27% Today? ↗
Mira Pharmaceuticals stock is falling on Tuesday but that's only after shares of MIRA underwent a massive rally on Monday. 
Via InvestorPlace
News headline image
Why Is TransCode Therapeutics (RNAZ) Stock Down 62% Today? ↗
TransCode Therapeutics stock is down on Tuesday after the biopharmaceutical company priced a public offering of RNAZ shares. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.